Matches in SemOpenAlex for { <https://semopenalex.org/work/W3178702632> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W3178702632 endingPage "744" @default.
- W3178702632 startingPage "725" @default.
- W3178702632 abstract "Managed entry agreements (MEAs) are arrangements between a manufacturer and payer/ health care provider that grant access (coverage/reimbursement) to a health technology, subject to fulfillment of specific conditions. An increasing number of payers in different countries are implementing MEAs to enable timelier access to cancer therapies. Novel chimeric antigen receptor (CAR) T-cell therapies are one such example where MEAs can play a prominent role in accelerating patient access. CAR-T therapies are administered to patients as a single, one-time treatment. ‘Spread payment’ models can help to reduce the (front-loaded) cost impact on payers’ annual health care budgets. Furthermore, CAR-T therapies are associated with uncertainty around their clinical and economic value proposition, whilst data on their long-term safety and clinical effectiveness are pending. Such uncertainty can be ameliorated, in the most part, through outcomes based MEAs, where payments can be made in installments, according to patient outcomes that are observed in routine clinical practice. Well-validated and objective measures are however prerequisite to successful outcomes-based schemes, as is high quality data together with the ease of implementation. A systematic review of the published literature over a 5-year period (2015–2020) was performed to better understand the nature of outcomes-based MEAs employed to date, as a conditional requirement for the reimbursement of CAR-T therapies. Their applicability to, and suitability for, a future generation of CAR-T therapies in development for multiple myeloma (MM) are considered, drawing on the recent experience from regulatory approved CAR-Ts in acute lymphocytic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL)." @default.
- W3178702632 created "2021-07-19" @default.
- W3178702632 creator A5002834977 @default.
- W3178702632 creator A5007062029 @default.
- W3178702632 creator A5039999880 @default.
- W3178702632 date "2021-07-09" @default.
- W3178702632 modified "2023-09-26" @default.
- W3178702632 title "Solving the problem of financing one-time treatments with evidence uncertainty: which types of outcomes-based payment models could work best for novel CAR-T therapies in multiple myeloma? A systematic review of the published literature" @default.
- W3178702632 doi "https://doi.org/10.18609/cgti.2021.104" @default.
- W3178702632 hasPublicationYear "2021" @default.
- W3178702632 type Work @default.
- W3178702632 sameAs 3178702632 @default.
- W3178702632 citedByCount "0" @default.
- W3178702632 crossrefType "journal-article" @default.
- W3178702632 hasAuthorship W3178702632A5002834977 @default.
- W3178702632 hasAuthorship W3178702632A5007062029 @default.
- W3178702632 hasAuthorship W3178702632A5039999880 @default.
- W3178702632 hasConcept C10138342 @default.
- W3178702632 hasConcept C126322002 @default.
- W3178702632 hasConcept C127413603 @default.
- W3178702632 hasConcept C145097563 @default.
- W3178702632 hasConcept C162118730 @default.
- W3178702632 hasConcept C162324750 @default.
- W3178702632 hasConcept C18762648 @default.
- W3178702632 hasConcept C189708586 @default.
- W3178702632 hasConcept C2776364478 @default.
- W3178702632 hasConcept C2779473830 @default.
- W3178702632 hasConcept C41008148 @default.
- W3178702632 hasConcept C55493867 @default.
- W3178702632 hasConcept C71924100 @default.
- W3178702632 hasConcept C78519656 @default.
- W3178702632 hasConcept C86803240 @default.
- W3178702632 hasConceptScore W3178702632C10138342 @default.
- W3178702632 hasConceptScore W3178702632C126322002 @default.
- W3178702632 hasConceptScore W3178702632C127413603 @default.
- W3178702632 hasConceptScore W3178702632C145097563 @default.
- W3178702632 hasConceptScore W3178702632C162118730 @default.
- W3178702632 hasConceptScore W3178702632C162324750 @default.
- W3178702632 hasConceptScore W3178702632C18762648 @default.
- W3178702632 hasConceptScore W3178702632C189708586 @default.
- W3178702632 hasConceptScore W3178702632C2776364478 @default.
- W3178702632 hasConceptScore W3178702632C2779473830 @default.
- W3178702632 hasConceptScore W3178702632C41008148 @default.
- W3178702632 hasConceptScore W3178702632C55493867 @default.
- W3178702632 hasConceptScore W3178702632C71924100 @default.
- W3178702632 hasConceptScore W3178702632C78519656 @default.
- W3178702632 hasConceptScore W3178702632C86803240 @default.
- W3178702632 hasIssue "7" @default.
- W3178702632 hasLocation W31787026321 @default.
- W3178702632 hasOpenAccess W3178702632 @default.
- W3178702632 hasPrimaryLocation W31787026321 @default.
- W3178702632 hasRelatedWork W2047345996 @default.
- W3178702632 hasRelatedWork W2315300816 @default.
- W3178702632 hasRelatedWork W2327940528 @default.
- W3178702632 hasRelatedWork W2340613125 @default.
- W3178702632 hasRelatedWork W2360955809 @default.
- W3178702632 hasRelatedWork W2404733967 @default.
- W3178702632 hasRelatedWork W2435227317 @default.
- W3178702632 hasRelatedWork W2748952813 @default.
- W3178702632 hasRelatedWork W2899084033 @default.
- W3178702632 hasRelatedWork W4242394070 @default.
- W3178702632 hasVolume "7" @default.
- W3178702632 isParatext "false" @default.
- W3178702632 isRetracted "false" @default.
- W3178702632 magId "3178702632" @default.
- W3178702632 workType "article" @default.